Bayer's Apollo Deal and Delayed Roundup Hearing Put September in the Spotlight
Published on 08/22/2026 at 13:12 | Redaktion boerse-global.de
The calendar is stacking up for Bayer. A €3 billion capital injection from private equity firm Apollo is set to reshape the company's balance sheet, while a key court hearing in its long-running glyphosate litigation has been pushed back to mid-September. Together, the developments offer investors a clearer picture of both the conglomerate's deleveraging trajectory and the timeline for resolving its most persistent legal overhang.
Apollo Transaction Accelerates Debt Reduction
Bayer has struck an agreement with Apollo-managed funds for a minority stake in a newly established entity housing its long-acting reversible contraception (LARC) business. The deal brings €3.0 billion in capital to the German group, with completion anticipated in the third quarter of 2026, according to Handelsblatt.
The balance-sheet impact is substantial. Bayer now expects net financial debt at year-end to land between €29 billion and €30 billion, a notable downward revision from its earlier guidance of €32 billion to €33 billion. The adjustment largely reflects the Apollo capital infusion.
For a company that has labored under the debt burden inherited from its Monsanto acquisition, the transaction signals a deliberate strategy: Bayer is leveraging minority investment structures to reclaim financial flexibility without surrendering full control of a business line. Apollo will hold a non-controlling stake in the new entity.
The deleveraging push builds on momentum from recent quarterly results. Just over a week ago, Bayer reported second-quarter adjusted EBITDA of €2.14 billion, beating the consensus estimate of €1.94 billion, propelled by Crop Science, where operating profit surged nearly 30 percent. Full-year guidance remains unchanged, with revenue projected between €44.7 billion and €47.0 billion and core earnings per share of €4.10 to €4.80.
Should investors sell immediately? Or is it worth buying Bayer?
Glyphosate Hearing Pushed to September
On the legal front, the glyphosate saga continues its slow grind. A hearing scheduled for August 19 to approve the class-action settlement before a Missouri court has been postponed to September 14, following a joint request from Monsanto and plaintiffs' attorneys.
The settlement, agreed in February, provides for payments of up to $7.25 billion spread over a maximum of 21 years. Bayer had previously received a boost from the U.S. Supreme Court, which ruled in June that federal law takes precedence over state law regarding warning labels — a decision that undermines thousands of lawsuits alleging inadequate cancer warnings.
The delay itself is unlikely to alter the settlement's fundamental terms, but it extends the period of uncertainty. Investors have long viewed the final resolution of glyphosate liabilities as the single most important catalyst for a sustained re-rating of the stock.
Pipeline Progress on Two Fronts
Beyond the headline financial and legal news, Bayer delivered operational advances across its divisions. The company made its first milestone payment under a collaboration with MustGrow Biologics, a partnership dating back to late 2023 focused on mustard-based biocontrol technologies for soil protection. Bayer holds exclusive rights for Europe, the Middle East and Africa under the agreement, which carries a total value of $35 million to $40 million spread over five to seven years. The initial payment signals that the technology has cleared an early development hurdle.
On the pharma side, Bayer will present eleven scientific abstracts at the European Society of Cardiology congress in Munich from August 28 to 31. The spotlight falls on new Phase III data for Kerendia (finerenone) in chronic kidney disease, along with results for the investigational drug asundexian. Particular attention will focus on the pooled INFINITY analysis, which examines Kerendia's effects in patients with and without atherosclerotic cardiovascular disease. The cardiovascular pipeline ranks among Bayer's most important growth areas.
Shares Hold Above Key Technical Level
Despite the flurry of news, the stock closed Friday at €47.90, down 0.9 percent on the day. The shares remain 2.4 percent above their 50-day moving average of €46.78, and the relative strength index at 50.1 points to a neutral market stance — neither overbought nor oversold. Over the past month, the stock has gained 2.8 percent, and it is up 29 percent since the start of the year.
The near-term trading pattern suggests investors are weighing the positive signals from the Apollo deal and pipeline progress against the lingering uncertainty of the legal calendar. With the rescheduled hearing now set for September 14, that date looms as the next significant test — not just for the litigation outlook, but for whether the stock's recent advance can be sustained.
Ad
Bayer Stock: New Analysis - 22 August
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
